Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lorcaserin

- PMLiVE

Seattle Genetics claims key US approval for Adcetris

Becomes the first new treatment for advanced Hl in more than 40 years

- PMLiVE

Novo Nordisk’s semaglutide obesity trial hits the mark

The injection helped adults lose up to 13.8% of their body weight in a year

- PMLiVE

FDA approves another home genetic testing service

23andMe’s kit will check for an increased risk of certain cancers developing

- PMLiVE

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

The duo will start a series of clinical trials combining the multiple RTK inhibitor and Keytruda

EISAI

NICE reverses its rejection of Eisai’s Lenvima

The cost-effectiveness watchdog has now backed the thyroid cancer treatment

dengue fever mosquito

Takeda gets FDA fast-track status for Zika vaccine

The phase I candidate also has the backing of US federal funding body BARDA

- PMLiVE

Health coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

- PMLiVE

NICE set to reject wider use of Eisai’s Halaven

Issues draft guidance recommending against second-line use in breast cancer

Eisai launches location tracker for dementia patients

Collaborates with Japanese smartphone app network Mamorio on the new tool

- PMLiVE

Porterhouse Medical expands into the US

UK med comms group opens new subsidiary in Philadelphia

Nobody knew healthcare was so complicated

short term and long term solutions

- PMLiVE

FDA panel backs Indivior’s drug to fight opioid addiction

The former RB pharma unit hopes for sales in the $1bn region

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links